HBsAg阳性活体供肾移植至HBsAg阴性受者的临床结局:中国高容量中心研究
该回顾性研究纳入83例HBsAg阳性活体供肾移植至HBsAg阴性受者,以384例HBcAb阳性供至HBcAb阴性受者为对照。HBsAb阳性受者移植肾及患者存活良好且无HBV传播,HBsAb-/HBcAb-受者传播风险较高。
要点
- HBsAb阳性受者接受HBsAg阳性供肾无HBV传播,移植物及患者存活良好
- HBsAb-/HBcAb-受者HBsAg阳转、HBV DNA阳转及死亡风险显著更高
核心结论
- HBsAb阳性受者接受HBsAg阳性活体供肾移植可获得良好移植物和患者存活且无HBV传播。
- HBsAb-/HBcAb-受者接受此类移植的HBV传播风险较高,需权衡风险与获益。
研究设计与样本
- 回顾性研究,纳入83例HBsAg阳性供者至HBsAg阴性受者的活体肾移植病例。
- 对照为384例HBcAb阳性供者至HBcAb阴性受者的活体肾移植病例。
主要发现
- 3例HBsAg阳转受者移植前均为HBsAb-/HBcAb-。
- 移植物功能、排斥反应、感染和移植物丢失两组无显著差异。
- 单因素分析显示,移植前HBsAb-/HBcAb-的受者HBsAg阳转、HBV DNA阳转和死亡风险显著更高。
关键数值与推荐
- 实验组24例供者(28.9%)移植前HBV DNA阳性,20例受者HBsAb阴性。
- 实验组全部83例受者接受HBV预防,对照组均未接受预防。
临床怎么用
- 对HBsAb阳性受者,可考虑接受HBsAg阳性活体供肾移植,需规范HBV预防。
- 对HBsAb-/HBcAb-候选者,应充分评估HBV传播风险与移植获益。
局限性
- 回顾性研究设计。
- 单中心高容量中心数据。
- 样本量有限(实验组83例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Data on kidney transplantation (KTx) from hepatitis B surface antigen (HBsAg)-positive (HBsAg+) donors to HBsAg-negative (HBsAg-) recipients [D(HBsAg+)/R(HBsAg-)] are limited. We aimed to report the outcomes of D(HBsAg+)/R(HBsAg-) KTx in recipients with or without hepatitis B surface antibody (HBsAb). METHODS: Eighty-three D(HBsAg+)/R(HBsAg-) living KTx cases were retrospectively identified. The 384 cases of KTx from hepatitis B core antibody-positive (HBcAb+) living donors to HBcAb-negative (HBcAb-) recipients [D(HBcAb+)/R(HBcAb-)] were used as the control group. The primary endpoint was posttransplant HBsAg status change from negative to postive (-- →+). RESULTS: Before KTx, 24 donors (28.9%) in the D(HBsAg+)/R(HBsAg-) group were hepatitis B virus (HBV) DNA positive, and 20 recipients were HBsAb-. All 83 D(HBsAg+)/R(HBsAg-) recipients received HBV prophylaxis, while no D(HBcAb+)/R(HBcAb-) recipients received prophylaxis. After a median follow-up of 36 months (range, 6-106) and 36 months (range, 4-107) for the D(HBsAg+)/R(HBsAg-) and D(HBcAb+)/R(HBcAb-) groups, respectively, 2 of 83 (2.41%) D(HBsAg+)/R(HBsAg-) recipients and 1 of 384 (0.26%) D(HBcAb+)/R(HBcAb-) became HBsAg+, accompanied by HBV DNA-positive (P = .083). The 3 recipients with HBsAg-→+ were exclusively HBsAb-/HBcAb- before KTx. Recipient deaths were more frequent in the D(HBsAg+)/R(HBsAg-) group (6.02% vs 1.04%, P = .011), while liver and graft function, rejection, infection, and graft loss were not significantly different. In univariate analyses, pretransplant HBsAb-/HBcAb- combination in the D(HBsAg+)/R(HBsAg-) recipients carried a significantly higher risk of HBsAg-→+, HBV DNA-→+, and death. CONCLUSIONS: Living D(HBsAg+)/R(HBsAg-) KTx in HBsAb+ recipients provides excellent graft and patient survivals without HBV transmission. HBV transmission risks should be more balanced with respect to benefits of D(HBsAg+)/R(HBsAg-) KTx in HBsAb-/HBcAb- candidates.
引用
- Wang XD, Liu JP, Song TR, et al. Kidney Transplantation From Hepatitis B Surface Antigen (HBsAg)-Positive Living Donors to HBsAg-Negative Recipients: Clinical Outcomes at a High-Volume Center in China. Clin Infect Dis. 2021. PMID: 32100025. doi:10.1093/cid/ciaa178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。